The efficacy of switching basal-bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an a-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching.
The efficacy of switching basal-bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an a-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching. Diabetol Int. 2024 Jan; 15(1):99-108.